OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr McCann on the Biologic Heterogeneity Within HER2+ Breast Cancer

May 26th 2025

Kelly E. McCann, MD, PhD, discusses the biologic heterogeneity within HER2-positive breast cancer and highlights the clinical implications of HR status in this disease subset.

Dr Bekaii-Saab on the RATIONALE-306 Study of Tislelizumab Plus Chemotherapy in Esophageal Cancer

May 26th 2025

Tanios S. Bekaii-Saab, MD, FACP, discusses the use of tislelizumab plus chemotherapy in unresectable or metastatic ESCC.

Dr Tang on the Implementation of Metastasis-Directed Radiotherapy in Oligometastatic ccRCC

May 23rd 2025

Chad Tang, MD, discusses potential roadblocks for the clinical use of metastasis-directed radiotherapy for patients with oligometastatic ccRCC.

Dr Patel on Ongoing Research With Subcutaneous Bispecific Antibodies in Frontline Follicular Lymphoma

May 23rd 2025

Vivek G. Patel, MD, discusses the potential advantages of subcutaneous bispecific antibodies that are being evaluated in frontline follicular lymphoma.

Dr Ip on the Limitations of Real-World CAR T-Cell Therapy Research in LBCL

May 23rd 2025

Andrew Ip, MD, discusses how the limitations of real-world studies reveal gaps in LBCL research that future CAR T-cell therapy clinical trials may address.

Dr Wang on Key Findings From a Study of the Tumor Microenvironment in ccRCC

May 23rd 2025

Yufei Wang, PhD, discusses how the metastasis of ccRCC could rewire the tumor microenvironment and lead to increased immunosuppression and fibrosis.

Dr Ghia on OS Outcomes With Ibrutinib/Venetoclax in CLL Relative to a Matched Healthy Population

May 23rd 2025

Paolo Ghia, MD, PhD, discusses the rationale for conducting an OS analysis of fixed-duration ibrutinib plus venetoclax in patients with CLL.

Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer

May 23rd 2025

Taliya Lantsman, MD, discusses future research directions for assessing dostarlimab/chemotherapy in endometrial cancer in the real-world setting.

Dr Matrana on the Importance of Combination Therapies in Metastatic RCC

May 23rd 2025

Marc R. Matrana, MD, emphasizes the need for combination therapies for the treatment of patients with advanced or metastatic renal cell carcinoma.

Dr Bhat on Choosing Between Pirtobrutinib and Liso-Cel for R/R CLL Management

May 23rd 2025

Seema A. Bhat, MD, discusses disease features and patient characteristics that inform the choice between pirtobrutinib and liso-cel for CLL.

Dr Vasquez on NAPRT as a Potential Biomarker for NAMPT Inhibition in Pediatric Rhabdomyosarcoma

May 22nd 2025

Juan Vasquez, MD, discusses how loss of NAPRT expression may serve as a biomarker for antitumor activity with NAMPT inhibition in rhabdomyosarcoma.

Dr Sekeres on the Methods and Design of a Study Evaluating Smoking Implications in MDS

May 22nd 2025

Mikkael A. Sekeres, MD, discusses the design of a study assessing the correlation between smoking intensity and genetic mutations in patients with MDS.

Dr Fonseca on Selecting a Treatment in Relapsed/Refractory Myeloma

May 22nd 2025

Rafael Fonseca, MD, discusses factors for selecting a treatment in relapsed/refractory multiple myeloma.

Dr Jain on Current Challenges in Defining Venetoclax Failure in CLL

May 21st 2025

Dr Zonder on the Importance of Personalized Medicine in Multiple Myeloma

May 21st 2025

Jeffrey Zonder, MD, discusses the importance of personalized medicine in the treatment of multiple myeloma.

Dr Vonderheide on Responses With RAS(ON) Inhibition in Preclinical Pancreatic Cancer Models

May 20th 2025

Robert Herman Vonderheide, MD, DPhil, discussed potential immune responses with immunotherapy plus KRAS inhibition in pancreatic cancer models.

Dr Fakih on the FDA Approval of Retifanlimab for Advanced Anal Cancer

May 20th 2025

Marwan Fakih, MD, discusses the clinical relevance of the FDA’s approval of retifanlimab for patients with squamous cell carcinoma of the anal canal.

Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

May 20th 2025

Lorenzo Falchi, MD, discusses the safety and pharmacodynamics of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma

Dr Tykodi on the Current Limitations of Cabozantinib-Based Triplets in Advanced RCC

May 20th 2025

Scott Tykodi, MD, PhD, discusses the challenges with developing effective, less toxic triplet regimens for patients with advanced RCC.

Dr Facon on the Rationale for Evaluating Isa-VRd in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

May 20th 2025

Thierry Facon, MD, details the rationale for evaluating Isa-VRd in patients with transplant-ineligible, newly diagnosed multiple myeloma.

x